Long-Term Safety of DMTs: What We Know and What We Need to Know
- Author
- ReachMD
- Published
- Fri 24 Jan 2025
- Episode Link
- http://reachmd.com/programs/cme/long-term-safety-of-dmts-what-we-know-and-what-we-need-to-know/32226/
CME credits: 1.00
Valid until: 24-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/long-term-safety-of-dmts-what-we-know-and-what-we-need-to-know/32226/
Valid until: 24-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/long-term-safety-of-dmts-what-we-know-and-what-we-need-to-know/32226/
This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
